Nervous System and COVID-19

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 2702

Special Issue Editors


E-Mail Website
Guest Editor
Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Interests: stroke; cerebrovascular Diseases; COVID-19; neuroimaging; brain sonography; cerebral amyloid angiopathy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Reggio Emilia, Italy
2. Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Interests: COVID-19; movement disorders; deep brain stimulation; speech disorders; neuro-oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Since the beginning of 2020, healthcare workers around the world have been facing challenges linked to the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new virus which first emerged in Wuhan, China. COVID-19 infection presents complex clinical features, far beyond the first described pneumonia cases in Wuhan, with a frequent involvement of the peripheral and central nervous system. Indeed, a broad spectrum of neurological consequences has been associated with COVID-19 infection. Acute neurological symptoms and manifestations can include fatigue, headache, myalgia, confusion, stroke, seizure, insomnia, anosmia, and ageusia, while subacute neurological conditions include encephalitis, Guillain–Barre syndrome, polyneuritis, myelitis, generalized myoclonus, and opsoclonus. These COVID-19 neurological manifestations have been linked to several pathophysiological mechanisms. Although extensively investigated, many issues of neurological involvement in COVID-19 infection need to be clarified, including the detailed clinical course of patients with neuro-COVID-19, the impact of pre-existing neurological diseases on infection, the long-term consequences of COVID-19 infection on the nervous system, and its possible role as a trigger for the development of neurodegenerative diseases.  

Thus, this Special Issue focuses on generating valuable scientific knowledge on the neurological consequences of COVID-19 and its mechanisms and associated clinical, biological, and neuroimaging issues. 

We sincerely look forward to receiving your contributions.

You may choose our Joint Special Issue in NeuroSci.

Dr. Maria Luisa Zedde
Dr. Francesco Cavallieri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • neuro-COVID
  • nervous system
  • coronavirus

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 490 KiB  
Review
COVID-19 and Parkinsonism: A Critical Appraisal
by Francesco Cavallieri, Valentina Fioravanti, Francesco Bove, Eleonora Del Prete, Sara Meoni, Sara Grisanti, Marialuisa Zedde, Rosario Pascarella, Elena Moro and Franco Valzania
Biomolecules 2022, 12(7), 970; https://doi.org/10.3390/biom12070970 - 11 Jul 2022
Cited by 16 | Viewed by 2249
Abstract
A few cases of parkinsonism linked to COVID-19 infection have been reported so far, raising the possibility of a post-viral parkinsonian syndrome. The objective of this review is to summarize the clinical, biological, and neuroimaging features of published cases describing COVID-19-related parkinsonism and [...] Read more.
A few cases of parkinsonism linked to COVID-19 infection have been reported so far, raising the possibility of a post-viral parkinsonian syndrome. The objective of this review is to summarize the clinical, biological, and neuroimaging features of published cases describing COVID-19-related parkinsonism and to discuss the possible pathophysiological mechanisms. A comprehensive literature search was performed using NCBI’s PubMed database and standardized search terms. Thirteen cases of COVID-19-related parkinsonism were included (7 males; mean age: 51 years ± 14.51, range 31–73). Patients were classified based on the possible mechanisms of post-COVID-19 parkinsonism: extensive inflammation or hypoxic brain injury within the context of encephalopathy (n = 5); unmasking of underlying still non-symptomatic Parkinson’s Disease (PD) (n = 5), and structural and functional basal ganglia damage (n = 3). The various clinical scenarios show different outcomes and responses to dopaminergic treatment. Different mechanisms may play a role, including vascular damage, neuroinflammation, SARS-CoV-2 neuroinvasive potential, and the impact of SARS-CoV-2 on α-synuclein. Our results confirm that the appearance of parkinsonism during or immediately after COVID-19 infection represents a very rare event. Future long-term observational studies are needed to evaluate the possible role of SARS-CoV-2 infection as a trigger for the development of PD in the long term. Full article
(This article belongs to the Special Issue Nervous System and COVID-19)
Show Figures

Figure 1

Back to TopTop